Sunday, 16 September 2018

Joint HCC UK / ILCA Grand Rounds Session

 Aileen Marshall, PhD (United Kingdom)

  • Bettina Buchholz, MD (United Kingdom)

    47 year old chronic HCV, relapse after DAA treatment. Indeterminate liver lesion detected on surveillance. Increased in size on subsequent imaging to 3.7 cm and thought to be consistent with HCC. Elevated AFP. Evidence of portal hypertension therefore first treatment TAE and liver transplant assessment. TAE performed but post transplant scans lesion had grown and appeared atypical therefore biopsy performed. Histology showed mixed HCC and cholangiocarcinoma.

  • Alexa Childs, MD (United Kingdom)

    60 year old patient with cirrhosis and haemochromatosis. October 2014: multifocal HCC, no evidence of portal hypertension. Initially planned for TACE-2 trial. January 2015: new right anterior portal vein occlusion, not included in TACE 2 trial, recommended to treat with TAE off study. Feb 2015: re-staging disease progression with infiltration left PV: unable to perform TAE. March 2015 to May 2015 treatment with Sorafenib, but disease progression. 16th June 2015, commenced Nivolumab on BMS040 trial with partial response.